Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

45.56USD
1:30pm EST
Change (% chg)

$0.48 (+1.06%)
Prev Close
$45.08
Open
$45.39
Day's High
$45.70
Day's Low
$45.19
Volume
1,405,271
Avg. Vol
2,594,425
52-wk High
$45.70
52-wk Low
$36.76

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $77,898.13
Shares Outstanding(Mil.): 1,728.00
Dividend: 0.26
Yield (%): 2.35

Financials

  ABT.N Industry Sector
P/E (TTM): 62.96 29.14 29.88
EPS (TTM): 0.72 -- --
ROI: 2.73 13.58 13.08
ROE: 5.09 14.48 14.24

Diagnostic company Alere to delay filing annual report

Alere Inc said it would delay filing its 2016 annual report, in the latest blow to the diagnostic company engaged in a legal battle with Abbott Laboratories over their deal.

11:02am EST

UPDATE 2-Diagnostic company Alere to delay filing annual report

March 1 Alere Inc said it would delay filing its 2016 annual report, in the latest blow to the diagnostic company engaged in a legal battle with Abbott Laboratories over their deal.

11:02am EST

BRIEF-FTC approves final order settling charges for Abbott's deal with St. Jude Medical

* Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive

Feb 23 2017

BRIEF-Abbott Laboratories commences exchange offers, consent solicitations for St. Jude Medical notes

* Abbott laboratories - Abbott commences exchange offers and consent solicitations for St. Jude Medical LLC notes Source text for Eikon: Further company coverage:

Feb 21 2017

BRIEF-Abbott Laboratories says board of directors shall consist of 12 persons from 11

* Abbott Laboratories-on Feb 16, amended by-laws to provide that co's board of directors shall consist of 12 persons, effective as of February 16, 2017

Feb 17 2017

BRIEF-ABBOTT SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE

* SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE Source text for Eikon: Further company coverage:

Feb 17 2017

Abbott Laboratories may see boost from St. Jude's acquisition: Barron's

NEW YORK Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron's said on Sunday.

Feb 12 2017

BRIEF-FDA grants Abbott first commercial authorization for molecular test to detect zika virus using whole blood

* U.S. FDA grants Abbott the first commercial authorization for a molecular test to detect zika virus using whole blood

Feb 02 2017

BRIEF-Abbott announces U.S. approval for its Assurity Mri pacemaker

* Abbott announces U.S. approval for its Assurity Mri pacemaker, the world's smallest, longest-lasting wireless mri-compatible pacemaker Source text for Eikon: Further company coverage:

Feb 01 2017

Abbott pauses on deals, to focus on St. Jude integration

Abbott Laboratories said it planned to focus on slashing its debt and integrating its $25 billion acquisition of St. Jude Medical in 2017, in a break from the hectic pace of dealmaking last year

Jan 25 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.95 +1.74
Pfizer Inc. (PFE.N) $34.49 +0.37
Novartis AG (NOVN.S) CHF78.75 +0.35
Merck & Co., Inc. (MRK.N) $66.47 +0.60
Sanofi SA (SASY.PA) €82.82 +1.49
AstraZeneca plc (AZN.L) 4,676.50 +32.50
GlaxoSmithKline plc (GSK.L) 1,666.50 +18.50
Eli Lilly and Co (LLY.N) $83.68 +0.87
Amgen, Inc. (AMGN.OQ) $178.91 +2.38
Boston Scientific Corporation (BSX.N) $24.90 +0.34

Earnings vs. Estimates